ARTICLE | Clinical News
ABI-H0731: Ph I started
November 10, 2016 11:22 PM UTC
Assembly began a single-blind, placebo-controlled, New Zealand Phase I trial of oral ABI-H0731 in about 114 subjects. The first part will evaluate multiple doses of oral ABI-H0731 for 1, 7 or 28 days ...
BCIQ Company Profiles
BCIQ Target Profiles